Harmony Biosciences named Glenn Reicin chief financial officer effective immediately, replacing Sandip Kapadia. The company said Reicin will oversee finance, including planning and analysis, accounting, treasury, investor relations and risk management.
The appointment comes as Harmony reaffirmed its 2026 net product revenue guidance of $1.0 billion to $1.04 billion. That is the same range the company is standing behind now, and it implies revenue above the $1 billion mark for the year.
Reicin joins after serving as CFO at Eccogene, where he helped build the company’s financial infrastructure to prepare it for an IPO. Before that, he was CFO and COO at Alladapt Immunotherapeutics, where he led fundraising and multiple financing initiatives. Earlier in his career, he spent 15 years at Morgan Stanley and four years as managing director of Skyline Ventures.
Chief Executive Jeffrey Dayno said the move comes as Harmony looks to leverage its balance sheet and push long-term growth. The company also said Kapadia helped strengthen its financial profile and support its growth strategy before departing. The market has reacted to these announcements by moving the company's shares -0.54% to a price of $27.44. Check out the company's full 8-K submission here.
